连亏两年再爆丑闻，济民健康副总裁伪造印章被立案调查

Core Viewpoint - Jimin Health (603222) is facing a significant crisis due to allegations against its Vice President He Qinghong and his team for forging company seals, leading to a police investigation and a stock market drop [1][2]. Group 1: Allegations and Investigation - The company announced that Vice President He Qinghong and his team are suspected of forging company seals, which meets the criteria for criminal investigation [1][2]. - The police have officially opened an investigation into the case, and the company is cooperating with authorities while planning to dismiss He Qinghong and reorganize the sales team [1][2]. Group 2: Legal Risks and Financial Implications - Jimin Health has received multiple legal notices from distributors claiming rights under supplementary agreements, demanding refunds and compensation for funds occupied [2][3]. - The investigation revealed that He Qinghong's team forged seals to sign agreements allowing distributors to return unsold products and receive compensation, which poses a risk of lawsuits against the company [2][3]. Group 3: Financial Performance - Jimin Health has reported losses for two consecutive years, with a net profit of -65.48 million yuan in 2023 and an expected net profit of -15 million to -10 million yuan for 2024 [4]. - The company attributed its losses to a significant decline in the sales of safety injection devices and impairment provisions related to equity repurchase and goodwill [4]. Group 4: Research and Development - In 2024, the company plans to invest approximately 41.52 million yuan in R&D, a 43.67% increase from the previous year, with ongoing development of cell therapy drugs and skincare products [5].